Apricus Biosciences Company Profile (NASDAQ:APRI)

About Apricus Biosciences

Apricus Biosciences logoApricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: APRI
  • CUSIP:
Key Metrics:
  • Previous Close: $0.35
  • 50 Day Moving Average: $0.34
  • 200 Day Moving Average: $0.59
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.81
  • P/E Growth: 0.00
  • Market Cap: $22.56M
  • Outstanding Shares: 66,350,000
  • Beta: 0.55
Additional Links:
Companies Related to Apricus Biosciences:

Analyst Ratings

Consensus Ratings for Apricus Biosciences (NASDAQ:APRI) (?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $2.23 (553.45% upside)

Analysts' Ratings History for Apricus Biosciences (NASDAQ:APRI)
Show:
DateFirmActionRatingPrice TargetDetails
3/15/2016Taglich BrothersLower Price TargetSpeculative Buy$4.25 -> $2.95View Rating Details
3/11/2016Dawson JamesReiterated RatingBuyView Rating Details
12/9/2015Sterne Agee CRTDowngradeBuy -> NeutralView Rating Details
11/6/2015Roth CapitalDowngradeBuy -> Neutral$1.50View Rating Details
8/13/2015Ascendiant Capital MarketsInitiated CoverageBuy$2.50View Rating Details
10/28/2014Cantor FitzgeraldDowngradeBuy -> HoldView Rating Details
(Data available from 8/25/2014 forward)

Earnings

Earnings History for Apricus Biosciences (NASDAQ:APRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q216($0.08)($0.05)$1.52 millionViewListenView Earnings Details
5/9/2016Q116($0.09)($0.09)ViewN/AView Earnings Details
3/9/2016Q415($0.11)($0.05)$1.81 million$2.60 millionViewListenView Earnings Details
11/5/2015Q315($0.11)($0.10)$1.42 million$1.30 millionViewListenView Earnings Details
8/5/2015Q2($0.13)($0.10)ViewListenView Earnings Details
5/11/2015Q1($0.10)($0.13)ViewListenView Earnings Details
3/16/2015Q4($0.12)($0.09)$1.90 millionViewListenView Earnings Details
11/10/2014Q314($0.10)($0.08)$1.23 million$1.90 millionViewN/AView Earnings Details
8/12/2014Q214($0.04)$0.05$5.45 million$5.50 millionViewN/AView Earnings Details
5/12/2014Q114($0.03)($0.09)$2.83 millionViewN/AView Earnings Details
3/17/2014Q212($0.06)($0.04)$2.00 million$0.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Apricus Biosciences (NASDAQ:APRI)
Current Year EPS Consensus Estimate: $-0.1700 EPS
Next Year EPS Consensus Estimate: $-0.0500 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.09)($0.08)($0.09)
Q2 20162($0.10)($0.06)($0.08)
Q3 20162($0.08)($0.07)($0.08)
Q4 20162($0.05)($0.03)($0.04)
Q1 20171($0.04)($0.04)($0.04)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171($0.02)($0.02)($0.02)
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Apricus Biosciences (NASDAQ:APRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Apricus Biosciences (NASDAQ:APRI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/3/2016Alexander J DennerMajor ShareholderBuy6,647,728$0.88$5,850,000.64View SEC Filing  
1/12/2016Alexander J DennerMajor ShareholderBuy1,306,819$0.88$1,150,000.72View SEC Filing  
12/29/2014Brian DorseyInsiderBuy10,000$1.05$10,500.00View SEC Filing  
12/22/2014Richard W PascoeCEOBuy10,000$1.02$10,200.00View SEC Filing  
10/23/2014Sandford D SmithDirectorBuy26,500$1.57$41,605.00View SEC Filing  
1/3/2014Leonard A OppenheimDirectorSell15,212$2.49$37,877.88View SEC Filing  
12/26/2013Kleanthis G XanthopoulosDirectorSell17,184$2.55$43,819.20View SEC Filing  
6/21/2013Kleanthis G XanthopoulosDirectorSell2,864$2.52$7,217.28View SEC Filing  
5/23/2013Richard W PascoeCEOBuy35,000$2.85$99,750.00View SEC Filing  
5/23/2013Rusty RayDirectorBuy5,000$2.85$14,250.00View SEC Filing  
5/23/2013Steven Robert MartinCFOBuy20,000$2.85$57,000.00View SEC Filing  
5/21/2013Kleanthis G XanthopoulosDirectorSell2,864$3.36$9,623.04View SEC Filing  
8/20/2012Edward M CoxVPBuy1,500$2.73$4,095.00View SEC Filing  
8/17/2012Rusty RayDirectorBuy4,000$2.81$11,240.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Apricus Biosciences (NASDAQ:APRI)
DateHeadline
capitalcube.com logoETF’s with exposure to Apricus Biosciences, Inc. : August 23, 2016 (NASDAQ:APRI)
www.capitalcube.com - August 23 at 3:36 PM
News IconAnalyst Buzz: Apricus Biosciences (APRI), Catalyst Pharmaceuticals ... - Newburg Press (NASDAQ:APRI)
newburghpress.com - August 22 at 8:40 PM
investornewswire.com logoApricus Biosciences, Inc (NASDAQ:APRI) Reports Sales Of $0.464, Surprising Estimates By -73.888% - Investor Newswire (NASDAQ:APRI)
www.investornewswire.com - August 22 at 8:40 PM
News IconHealthcare Stocks to Keep Your Eyes on: UnitedHealth Group Inc (NYSE:UNH), Apricus Biosciences Inc (NASDAQ:APRI) - Post Registrar (NASDAQ:APRI)
postregistrar.com - August 22 at 3:35 PM
News IconRatings & Crowd Appeal on Apricus Biosciences, Inc (NASDAQ:APRI) - Post News (NASDAQ:APRI)
www.kentuckypostnews.com - August 19 at 11:55 AM
News IconApricus Biosciences transfers UK marketing authorisation for Vitaros to Ferring Pharma (NASDAQ:APRI)
www.pharmabiz.com - August 18 at 11:56 AM
finance.yahoo.com logoApricus Biosciences Announces Completion of Transfer of the United Kingdom Marketing Authorization for Vitaros® to ... - Yahoo Finance (NASDAQ:APRI)
finance.yahoo.com - August 17 at 3:36 PM
investornewswire.com logoAnalysts See Sales Of $11.92 For Apricus Biosciences, Inc (NASDAQ:APRI) - Investor Newswire (NASDAQ:APRI)
www.investornewswire.com - August 16 at 3:36 PM
nasdaq.com logoApricus Biosciences Announces Completion of Transfer of the United Kingdom Marketing Authorization for Vitaros® to ... - Nasdaq (NASDAQ:APRI)
www.nasdaq.com - August 15 at 3:36 PM
finance.yahoo.com logoEdited Transcript of APRI earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:APRI)
finance.yahoo.com - August 15 at 3:36 PM
finanznachrichten.de logoAPRICUS BIOSCIENCES INC (NASDAQ:APRI)
www.finanznachrichten.de - August 15 at 10:47 AM
reuters.com logoBRIEF-Apricus Biosciences says gets $4.5 mln in upfront payments from Ferring (NASDAQ:APRI)
www.reuters.com - August 15 at 10:47 AM
rttnews.com logoApricus Biosciences Transfers UK Marketing Authorization For Vitaros To Ferring (NASDAQ:APRI)
www.rttnews.com - August 15 at 10:47 AM
publicnow.com logoApricus Biosciences Announces Completion of Transfer of the United Kingdom Marketing Authorization for Vitaros® to Ferring Pharmaceuticals (NASDAQ:APRI)
www.publicnow.com - August 15 at 10:47 AM
finance.yahoo.com logoAPRICUS BIOSCIENCES, INC. Financials (NASDAQ:APRI)
finance.yahoo.com - August 13 at 3:32 PM
streetinsider.com logoApricus Biosciences (APRI) Reports Completion of Transfer of Vitaros German Marketing Authorization (NASDAQ:APRI)
www.streetinsider.com - August 12 at 9:01 PM
capitalcube.com logoETF’s with exposure to Apricus Biosciences, Inc. : August 12, 2016 (NASDAQ:APRI)
www.capitalcube.com - August 12 at 3:44 PM
News IconStock Update on Apricus Biosciences, Inc. (NASDAQ:APRI) - Duncan Research (NASDAQ:APRI)
www.duncanindependent.com - August 11 at 9:27 PM
globenewswire.com logoApricus Biosciences Announces Completion of Transfer of Vitaros® German Marketing Authorization to Ferring ... - GlobeNewswire (press release) (NASDAQ:APRI)
globenewswire.com - August 11 at 12:46 PM
capitalcube.com logoApricus Biosciences, Inc. :APRI-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:APRI)
www.capitalcube.com - August 11 at 12:46 PM
streetinsider.com logoApricus Biosciences (APRI) Reports Completion of Transfer of ... - StreetInsider.com (NASDAQ:APRI)
www.streetinsider.com - August 10 at 10:00 PM
reuters.com logoBRIEF-Apricus Biosciences announces completion of transfer of Vitaros German marketing authorization to Ferring Pharmaceuticals (NASDAQ:APRI)
www.reuters.com - August 10 at 10:00 AM
finanznachrichten.de logoApricus Biosciences, Inc.: Apricus Biosciences Announces Completion of Transfer of Vitaros® German Marketing Authorization to Ferring Pharmaceuticals (NASDAQ:APRI)
www.finanznachrichten.de - August 10 at 10:00 AM
publicnow.com logoApricus Biosciences Announces Completion of Transfer of Vitaros® German Marketing Authorization to Ferring Pharmaceuticals (NASDAQ:APRI)
www.publicnow.com - August 10 at 10:00 AM
investornewswire.com logoApricus Biosciences, Inc (NASDAQ:APRI) Records An Estimated Annual Sales Mean Of $11.92 - Investor Newswire (NASDAQ:APRI)
www.investornewswire.com - August 9 at 12:20 PM
fortune.com logoApricus Biosciences, Inc. (NASDAQ:APRI) Insider Activities Are in ... - Review Fortune (NASDAQ:APRI)
reviewfortune.com - August 8 at 3:35 PM
benzinga.com logoWorst Performing Industries For August 5, 2016 - Benzinga (NASDAQ:APRI)
www.benzinga.com - August 5 at 11:57 AM
fortune.com logoAttention Grabbing Analyst Research Reports: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Apricus Biosciences Inc ... - Review Fortune (NASDAQ:APRI)
reviewfortune.com - August 5 at 11:57 AM
streetupdates.com logoPreview of Analysts Recommendation: Ocular Therapeutix, Inc. (NASDAQ:OCUL) , Apricus Biosciences, Inc (NASDAQ ... - Street Updates (NASDAQ:APRI)
www.streetupdates.com - August 5 at 11:57 AM
News IconMGT Capital Investments (NYSEMKT:MGT) & Apricus Biosciences ... - Money News (press release) (NASDAQ:APRI)
www.newsismoney.com - August 5 at 11:57 AM
rttnews.com logoEARNINGS SUMMARY: Details of Apricus Biosciences, Inc. Q2 Earnings Report (NASDAQ:APRI)
www.rttnews.com - August 4 at 9:18 PM
globenewswire.com logoApricus Biosciences Provides Corporate Update and Second Quarter Financial Results (NASDAQ:APRI)
globenewswire.com - August 4 at 9:18 PM
twst.com logoApricus Bioscience Inc.: Apricus Biosciences Provides Corporate Update and Second Quarter Financial Results (NASDAQ:APRI)
www.twst.com - August 4 at 9:18 PM
sg.finance.yahoo.com logoApricus reports 2Q loss (NASDAQ:APRI)
sg.finance.yahoo.com - August 4 at 9:18 PM
biz.yahoo.com logoApricus Biosciences Inc Earnings Call (Q2 2016) (NASDAQ:APRI)
biz.yahoo.com - August 4 at 12:03 PM
biz.yahoo.com logoQ2 2016 Apricus Biosciences Inc Earnings Release - 4:01 pm ET (NASDAQ:APRI)
biz.yahoo.com - August 4 at 12:03 PM
finance.yahoo.com logoApricus Biosciences to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:APRI)
finance.yahoo.com - August 3 at 12:08 PM
investornewswire.com logoApricus Biosciences, Inc (NASDAQ:APRI) Yearly Sales Target At $11.92 - Investor Newswire (NASDAQ:APRI)
www.investornewswire.com - August 2 at 8:18 AM
twst.com logoApricus Bioscience Inc.: Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call (NASDAQ:APRI)
www.twst.com - August 1 at 8:28 AM
publicnow.com logoApricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call (NASDAQ:APRI)
www.publicnow.com - August 1 at 7:21 AM
News IconApricus Biosciences, Inc. (NASDAQ:APRI) Upcoming Earnings: What matter for investors? - The Voice Registrar (NASDAQ:APRI)
voiceregistrar.com - July 29 at 3:33 PM
streetinsider.com logoApricus Biosciences (APRI) Receives Approval for Vitaros in Lebanon - StreetInsider.com (NASDAQ:APRI)
www.streetinsider.com - July 27 at 11:48 AM
globenewswire.com logoApricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon - GlobeNewswire (press release) (NASDAQ:APRI)
globenewswire.com - July 27 at 11:48 AM
publicnow.com logoApricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon (NASDAQ:APRI)
www.publicnow.com - July 27 at 7:18 AM
streetinsider.com logoApricus Biosciences (APRI) Announces Expansion of Vitaros Partnership (NASDAQ:APRI)
www.streetinsider.com - July 26 at 9:09 PM
reuters.com logoBRIEF-Apricus Biosciences expands existing partnership with Ferring Pharmaceuticals (NASDAQ:APRI)
www.reuters.com - July 26 at 9:09 PM
News IconApricus Biosciences Terminates One Agreement, Signs Another (NASDAQ:APRI)
sdbj.com - July 26 at 9:09 PM
reuters.com logoBRIEF-Apricus Biosciences expands existing partnership with Ferring Pharmaceuticals - Reuters (NASDAQ:APRI)
www.reuters.com - July 25 at 8:21 AM
nasdaq.com logoApricus Biosciences, Inc. : Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring ... - Nasdaq (NASDAQ:APRI)
www.nasdaq.com - July 25 at 8:21 AM
biz.yahoo.com logoAPRICUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events (NASDAQ:APRI)
biz.yahoo.com - July 25 at 7:06 AM

Social

Apricus Biosciences (NASDAQ:APRI) Chart for Thursday, August, 25, 2016


Last Updated on 8/25/2016 by MarketBeat.com Staff